PRODUCT PIPELINE


Blue Earth Diagnostics’ commitment is to develop and commercialise innovative radiopharmaceutical agents that have the potential to inform management decisions or treat patients with serious disease, such as cancer. These agents are designed to have a positive impact on patient care, with a focus on areas of significant unmet medical need. Here you can explore details of our research pipeline, arranged by product.


Product/Candidate
Potential Use
Application
Preclinical
Phase 1
Phase 2
Phase 3
Approved (US)
Approved (EU)

Fluciclovine(18F)

Suspected recurrent prostate cancer

PET imaging

Fluciclovine(18F)

Brain Metastases

PET imaging

rhPSMA-7.3(18F)

Prostate cancer

PET imaging

Our sister company, Blue Earth Therapeutics, continues to investigate the use of rhPSMA-10.1 as a therapeutic agent. For more information see https://www.blueearththerapeutics.com/pipeline


PP-UK-0533 / June 2022